MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturity, redemption or
sale of marketable...
$76,950K
Other
$62K
Net cash provided
by/(used in) investing...
$59,644K
Canceled cashflow
$17,368K
Net
(decrease)/increase in cash, cash...
-$65,428K
Canceled cashflow
$59,644K
Depreciation
$4,620K
Share-based compensation
expense
$1,990K
Increase in borrowings
and other...
$784K
Decrease in noncurrent
assets
-$562K
Amortization
$355K
Other
$56K
Proceeds from issuance of
common stock from...
$1,775K
Proceeds from exercise of
stock options
$10K
Investment in marketable
securities
$16,090K
Acquisition of property,
plant and equipment
$1,278K
Net cash (used
in)/provided by operating...
-$101,372K
Canceled cashflow
$8,367K
Net cash (used
in)/provided by financing...
-$23,666K
Effect of currency
exchange rate changes on...
-$34K
Canceled cashflow
$1,785K
Net (loss)/profit
-$77,924K
(decrease)/increase in payables and
other current...
-$11,407K
(increase)/decrease in receivables
and other operating...
$9,158K
Decrease in deferred
revenue
-$5,812K
Increase in inventories
$4,041K
Unrealized foreign
exchange gains
$888K
Accretion of
available-for-sale debt securities
$509K
Repayment of borrowings
$25,451K
Back
Back
Cash Flow
source: myfinsight.com
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)